Get notified of page updates

Breast Cancer

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
How To Use XRAY ›
Showing 1 through 10 out of 266

Relevance: High

Strength of Science: High

15 May 2025

Study : Enhertu shows promising results for HER2-low and HER2-ultralow metastatic breast cancer

Most relevant for: People with HR-positive metastatic breast cancer

Recent study results show that a new targeted treatment works better than standard chemotherapy for people with metastatic hormone receptor-positive breast cancers with low or ultralow HER2 status. (Posted 5/15/25)

READ MORE  ›

Relevance: Medium-High

Research Timeline: Post Approval

6 March 2025

Update : Ovarian suppression may reduce breast cancer recurrence

Most relevant for: Premenopausal women before or during early breast cancer treatment

Ovarian suppression—blocking estrogen production in the ovaries—can improve breast cancer outcomes in premenopausal women. This review provides information about ovarian suppression and describes who might benefit. (Posted 3/6/25)


Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Research Timeline: Post Approval

28 February 2025

Topic : Addressing the needs of young adults with breast cancer

Most relevant for: Young women with breast cancer concerned about survivorship issues

This update addresses common concerns faced by young adults with breast cancer, particularly fertility and childbearing, psychosocial health and treatment-related side effects. (Posted 2/28/25)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Strength of Science: Medium

13 February 2025

Study : Impact on sexual well-being among people with an inherited BRCA mutation

Most relevant for: People with an inherited mutation that increases cancer risk who are interested in sexual health

This study looked at sexual well-being in those with an inherited BRCA1 or BRCA2 mutation. Knowledge about having an inherited BRCA1 or BRCA1 mutation did not influence sexual health. However, menopause and cancer diagnosis was had a significant impact on sexual health and sexual function. (Posted 2/13/25)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

6 January 2025

Guideline : Hereditary cancer gene guidelines expand

Most relevant for: People at high risk for hereditary cancer

The National Comprehensive Cancer Network regularly updates guidelines for several types of hereditary cancer. These recommendations often change when new research is published. Recently, the NCCN expanded its guidelines to include information on hereditary prostate and gastric cancers. (Posted 1/6/25)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

10 December 2024

Study : Lifetime cancer risks in people with an inherited mutation in CDH1

Most relevant for: People with an inherited mutation in CDH1

This study looked at the lifetime risks of stomach and breast cancer in families with a known CDH1 mutation. Results from the study suggest that for some CDH1 mutation carriers lifetime stomach cancer risk is lower than previous research has shown. Additionally, study results show that the lifetime risk of breast cancer is similar to previous lifetime risk estimates in women with mutations in this gene. (Posted 12/10/24)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

14 November 2024

Study : Moderate exercise delays time to breast cancer recurrence

Most relevant for: People with breast cancer who are interested in using exercise to reduce risk of recurrence

For premenopausal women with early-stage breast cancer, physical activity may increase the time before cancer returns and spreads. In this study, people with hormone receptor-negative (HR-negative) breast cancer benefited from moderate exercise—more than those with hormone receptor-positive (HR-positive) breast cancer. This study found that outcomes improved when weekly exercise time was between 90 minutes and 5 hours.  (Posted 11/14/24)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

31 October 2024

Study : Impact of breast cancer and BRCA mutations on fertility preservation

Most relevant for: People considering fertility preservation.

Timely family planning discussions are important for people diagnosed with breast cancer as well as those who have an inherited a BRCA1 or BRCA2 mutation. This study looked at the number of mature eggs recovered when ovaries were stimulated for fertility preservation or preimplantation genetic testing among three groups and found that the number of eggs collected was similar. (Posted 10/31/24)

Este artículo está disponible en español.

READ MORE  ›

Relevance: Medium-High

Strength of Science: Medium-High

27 September 2024

Study : Use of cannabis for cancer symptom management

Most relevant for: People with cancer interested in using cannabis to help manage symptoms.

Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)

Este artículo está disponible en español.

READ MORE  ›

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

17 September 2024

Study : Combining two anti-HER2 drugs improves outcomes more effectively than one

Most relevant for: People with Her2-positive metastatic breast cancer

Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)

Este artículo está disponible en español.

READ MORE  ›